Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Active Ankylosing Spondylitis
NCT01870284Phase 3Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2014
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of ixekizumab in ankylosing spondylitis (AS), sponsored by Eli Lilly and Company. Planned start Jul 2014; status: withdrawn.
02
Drugs
ixekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01870284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01870284.